United States Veterinary Oncology Market By Animal Type (Canine, Feline, Equine), By Therapy (Radiotherapy, Surgery, Chemotherapy, Immunotherapy and Other Therapies), By Cancer Type (Skin Cancers, Lymphomas, Sarcomas and Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 469.19 Million
CAGR (2026-2031)	6.11%
Fastest Growing Segment	Canine
Largest Market	West
Market Size (2031)	USD 669.71 Million

Market Overview

The United States Veterinary Oncology Market will grow from USD 469.19 Million in 2025 to USD 669.71 Million by 2031 at a 6.11% CAGR. The United States Veterinary Oncology Market comprises a specialized sector dedicated to the diagnosis and treatment of cancer in companion animals through modalities such as chemotherapy, immunotherapy, radiation, and surgical interventions. The market is primarily propelled by the increasing humanization of pets, where owners view animals as integral family members, thereby driving demand for medical healthcare standards comparable to human medicine. This trajectory is further supported by the rising prevalence of geriatric pet populations and improvements in diagnostic capabilities. According to the American Veterinary Medical Association's '2024 Pet Ownership and Demographics Sourcebook', in 2024, the average amount spent per household on veterinary care for dogs was approximately $580, reflecting the substantial financial commitment owners are willing to dedicate to animal health.

Despite this growth, a significant challenge impeding broader market expansion is the prohibitive cost of specialized oncological treatments, which often exceeds the financial reach of many pet owners. While pet insurance sectors are expanding, the lack of universal coverage for expensive therapies remains a barrier to access. Consequently, economic constraints may force difficult decisions regarding treatment options, potentially limiting the widespread adoption of newer therapeutic interventions.

Key Market Drivers

Deepening Human-Animal Bond and Pet Humanization Trends fundamentally reshape the United States Veterinary Oncology Market as owners increasingly view companion animals as integral family members. This emotional shift drives a willingness to pursue costly cancer treatments such as chemotherapy and radiation which were previously reserved for human healthcare. Consequently the demand for specialized veterinary services has surged and bolstered the revenue of major industry players. According to Zoetis, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', sales of companion animal products in the United States increased 7% in the fourth quarter of 2024. This commercial growth underscores the financial commitment owners are making. Furthermore, according to the American Pet Products Association, March 2025, in the 'State of the Industry Report', spending on veterinary care and product sales in the United States reached $39.8 billion in 2024.

Increasing Penetration of Pet Health Insurance Coverage acts as a critical enabler for market expansion by mitigating financial barriers associated with advanced oncological therapies. Cancer treatments often incur costs that can be prohibitive for uninsured pet owners. The expansion of insurance policies provides a safety net that allows veterinarians to recommend procedures without immediate economic rejection. According to the North American Pet Health Insurance Association, April 2025, in the 'State of the Industry Report 2025', the total number of insured pets in North America reached 7.03 million at the end of 2024. This rising coverage rate directly correlates with increased access to specialized oncology services.

Download Free Sample Report

Key Market Challenges

The prohibitive cost of specialized cancer treatments constitutes a severe impediment to the growth of the United States Veterinary Oncology Market. Advanced interventions such as radiation therapy and immunotherapy involve high expenses that often exceed the disposable income of average pet owners. Consequently, when faced with a diagnosis, many clients are forced to forego curative options in favor of less expensive palliative care or euthanasia. This economic friction directly reduces the adoption rates of novel therapeutics and limits the revenue streams for veterinary clinics and pharmaceutical companies operating within this sector.

This market constraint is critically intensified by the insufficient prevalence of financial safety nets for animal healthcare. Most pet owners are responsible for the entirety of medical bills out-of-pocket, as comprehensive coverage remains rare. According to the North American Pet Health Insurance Association's '2025 State of the Industry Report', in 2024, the insurance penetration rate for dogs in the United States was only 5.46%. Such a low coverage statistic indicates that the majority of the potential patient base is financially vulnerable, thereby preventing the mass market commercialization of high-cost oncological solutions.

Key Market Trends

The Integration of Genomic Profiling for Precision Medicine is fundamentally altering clinical approaches by enabling veterinarians to tailor therapeutic strategies to the specific molecular alterations of a tumor. Rather than relying on empiric chemotherapy, practitioners are utilizing next-generation sequencing to identify actionable mutations and deploy targeted agents, a method that aligns veterinary protocols with human oncological standards. This shift toward individualized care is substantiated by growing clinical evidence regarding survival improvements in aggressive malignancies. According to FidoCure, May 2025, in the 'FidoCure Study Unlocks Breakthroughs in Deadliest Dog Cancer' press release, a study analyzing real-world data from 508 pet dog patients demonstrated that matching genomic biomarkers with targeted therapies resulted in significant survival benefits compared to standard protocols.

Concurrently, the Adoption of Artificial Intelligence in Diagnostic Imaging and Prognostics is enhancing decision-making precision by predicting therapeutic efficacy before treatment initiation. Advanced algorithms now analyze live cancer cell responses and clinical variables to forecast outcomes, thereby reducing trial-and-error prescribing and optimizing financial resources for owners. This technological integration is delivering quantifiable improvements in remission rates for complex cases where standard-of-care often fails. According to ImpriMed, December 2024, in the 'From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology' report, a validation study revealed that canine lymphoma patients treated with AI-predicted drug regimens achieved a 4-fold higher complete response rate compared to those receiving non-optimized therapies.

Segmental Insights

The canine segment represents the most rapidly expanding area within the United States veterinary oncology market. This growth is primarily driven by the rising prevalence of cancer among the aging dog population and a cultural shift towards pet humanization that encourages higher healthcare expenditure. Furthermore, the continued approval of species-specific treatments by the FDA Center for Veterinary Medicine has expanded available options, fostering greater adoption of oncology services. As veterinary professionals gain access to these targeted therapies, pet owners are increasingly electing to pursue comprehensive care, thereby sustaining the strong momentum of this segment.

Regional Insights

The West United States maintains a dominant position in the veterinary oncology market, driven by a high density of specialized referral centers and substantial pet healthcare expenditure. This regional leadership is supported by established academic infrastructure, including the University of California, Davis, which actively advances clinical research and treatment protocols for animal cancer. Additionally, the strong prevalence of insured pets and high disposable income levels in states like California allow owners to access comprehensive diagnostic and therapeutic options. These factors collectively foster a robust environment for oncology product adoption across the western states.

Recent Developments

• In March 2025, ELIAS Animal Health received full approval from the United States Department of Agriculture Center for Veterinary Biologics for its autologous cancer immunotherapy. This regulatory milestone marked the commercialization of the first licensed adoptive cell therapy for the treatment of canine osteosarcoma. The therapy, which involves conditioning the patient's immune system to recognize and attack cancer cells, was designed to be administered at authorized treatment centers across the country. This approval provided veterinary oncologists with a novel, evidence-based therapeutic option for a highly aggressive bone cancer, significantly advancing the landscape of available biological treatments.
• In October 2024, FidoCure presented breakthrough research findings regarding canine splenic hemangiosarcoma at the Veterinary Cancer Society Annual Conference. The company's study, which analyzed a large genomic dataset, identified specific genetic mutations associated with prognosis and demonstrated that dogs treated with targeted therapies or chemotherapy experienced improved survival rates compared to surgery alone. This research underscored the utility of genomic profiling in identifying effective small-molecule therapies for aggressive cancers. The presentation highlighted the company's commitment to advancing precision oncology and provided new evidence to support the integration of genomic data into clinical practice for canine cancer treatment.
• In May 2024, ImpriMed expanded its precision medicine offerings by launching the Drug Response Predictions service for canine patients diagnosed with lymphoma and leukemia. This artificial intelligence-driven solution utilized the company's proprietary database of clinical outcomes to forecast how individual patients would respond to specific chemotherapeutic agents and protocols. By analyzing live cancer cells and medical history, the service provided veterinarians with a personalized report to guide treatment decisions. The launch aimed to improve clinical outcomes and optimize therapeutic strategies for blood cancers, addressing a critical need for personalized care in the veterinary oncology sector.
• In January 2024, Antech Diagnostics announced the commercial launch of the Nu.Q Canine Cancer Test, an innovative in-clinic screening tool designed to operate on the company's Element i+ Immunodiagnostic Analyzer. Unveiled at the Veterinary Meeting & Expo in Orlando, this diagnostic breakthrough allowed veterinary professionals to assess a patient's risk for prevalent cancers, such as lymphoma and hemangiosarcoma, during routine visits. The test measured circulating nucleosomes in plasma to provide rapid results, enabling earlier detection and intervention. This launch represented a significant expansion of the company's molecular diagnostics portfolio within the United States veterinary oncology market.

Key Market Players

• Elanco Animal Health Incorporated
• Boehringer Ingelheim Animal Health USA Inc.
• Zoetis Inc
• Virbac Corporation
• Merck & Co., Inc.
• Ardent Animal Health, LLC
• Arizona Veterinary Oncology
• Varian Medical Systems, Inc.
• PetVet Care Centers
• Las Vegas Veterinary Specialty Cente

By Animal Type	By Therapy	By Cancer Type	By Region
Canine Feline Equine	Radiotherapy Surgery Chemotherapy Immunotherapy Other Therapies	Skin Cancers Lymphomas Sarcomas Others	Northeast Midwest South West

Report Scope:

In this report, the United States Veterinary Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Veterinary Oncology Market, By Animal Type:

• Canine
• Feline
• Equine

• United States Veterinary Oncology Market, By Therapy:

• Radiotherapy
• Surgery
• Chemotherapy
• Immunotherapy
• Other Therapies

• United States Veterinary Oncology Market, By Cancer Type:

• Skin Cancers
• Lymphomas
• Sarcomas
• Others

• United States Veterinary Oncology Market, By Region:

• Northeast
• Midwest
• South
• West